IMF Podcasts: Michael Kremer – Investing in Vaccines Now Would Buy Time, Save $Billions

In the early 2000s, Nobel Laureate, Michael Kremer helped develop the design of advance market commitment models (AMCs). They were used to incentivize the private sector to work on issues of relevance for the developing world by pledging that if they developed an appropriate vaccine, funds would be available for those countries to purchase it. The approach resulted in billions of dollars being devoted to pneumococcal vaccines for strains common in developing countries, saving hundreds of thousands of lives. Kremer’s latest research focuses on how to expedite the production and distribution of the COVID-19 vaccines immediately following successful medical trials. In this podcast, Kremer says at-risk investment into vaccine manufacturing capacity before clinical approval would advance vaccine distribution by 6 months or more. Michael Kremer shared the Nobel Memorial Prize in Economics in 2019 for his work on experimental approaches to alleviating global poverty. He was invited by the Institute for Capacity Development to present this latest research to IMF economists.  Transcript

Check out the University of Chicago’s podcast Pandemic Economics

Michael Kremer is Professor in Economics at the University of Chicago, and Director of the Development Innovation Lab.

Listen to the podcast from source

Tags assigned to this article:

You may have an interest in also reading…

Terrorist groups exploiting COVID-19 in Sahel, UN peacekeeping chief tells Security Council

Jean-Pierre Lacroix told the Security Council that the last six months have been particularly challenging as the G5 Sahel group

Kristalina Georgieva, IMF Managing Director: Event of the Finance Ministers on Financing for Development in the Era of COVID-19 and Beyond

AS PREPARED FOR DELIVERY. I would like to start by thanking Minister Freeland in her new role as Finance Minister.

UK Government: Over half a million people taking part in pioneering COVID-19 research

637,379 participants from across the UK have now taken part in public health research into the effects of, and treatment